BREAST CANCER

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.

A subgroup analysis showed that certain patients with breast cancer may benefit more from eribulin, and quality of life (QoL) data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.

Debu Tripathy, MD, discusses targeting HER2 in breast cancer.

Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses the background and results of a study looking at crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).

It has long been recognized that many breast tumors in postmenopausal women are hormone-dependent and that hormonal manipulation can alter the natural history of the disease. Learn more about the mechanism of action of fulvestrant (Faslodex).

New approaches to treating women with advanced ER+ breast cancer are in development, which includes both hormone therapy and combinations with targeted agents. The continuing goal is to understand disease biology and individualize treatment regimens to increase survival.

Jonathan D. Herman, MD, obstetrician and gynecologist at Hofstra North Shore - LIJ Medical School, discusses the findings from a survey looking at breast cancer risk perception.

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer (TNBC), but recent studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

Sandra Swain, MD, discusses pregnancy-related breast cancer.

The human epidermal growth factor receptors (known as the HER family) play a pivotal role in transmitting signals that regulate cell growth and survival.

Meredith C. Henderson, PhD, Head, R&D, Provista Diagnostics, describes the dtectDx Breast test.

The FDA’s Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab (Perjeta) in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Studies presented at the 2013 Breast Cancer Symposium investigated the efficacy and safety of various approaches to the treatment of HER2-positive breast cancer.

A pair of studies from the 2013 Breast Cancer Symposium delivered promising and preliminary news about the microtubule inhibitor eribulin mesylate.

An analysis of the T-PAS expanded access study of T-DM1 in previously treated HER2+ metastatic breast cancer confirmed existing information on the safety of the combination, and observed significant clinical activity in a patient population that averaged seven prior therapies.

New analyses of the BOLERO-2 trial indicate that everolimus and exemestane produced significantly longer PFS than placebo and exemestane in several previously unstudied patient subgroups.

Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.

Entinostat in combination with exemestane has been granted a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

Aditya Bardia, MD, MPH, Attending Physician, Massachusetts General Hospital, Harvard Medical School, gives an overview of the Snapshot assay for breast cancer.

Women with DCIS treated with radiation therapy had no increased risk of cardiovascular disease compared with women in the general population or women with DCIS treated with surgery.

Patients with DCIS who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence.

Naomi B. Boekel, MSc, discusses the results from a large study that showed that radiation therapy for DCIS does not seem to increase cardiovascular disease risk.

Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses patients' perception of breast cancer risk.